Table 1 Clinicopathological characteristics of the TCGA LIHC cohort
NSUN7 status | |||
|---|---|---|---|
Unmethylated (N = 221) | Methylated (N = 156) | p value* | |
Gender, n (%) | |||
Male | 143 (64.7) | 112 (71.8) | 0.180 |
Female | 78 (35.3) | 44 (28.2) | |
Age, n (%) | |||
≤ 60 years | 125 (56.8) | 55 (35.3) | < 0.001 |
> 60 years | 95 (43.2) | 101 (64.7) | |
Vascular invasion, n (%) | |||
Microvascular or macrovascular | 64 (34.2) | 47 (35.1) | 0.9056 |
None | 123 (65.8) | 87 (64.9) | |
ISHAK fibrosis score, n (%) | |||
0: No fibrosis | 47 (40.5) | 29 (28.4) | |
1,2: Portal fibrosis | 16 (13.8) | 15 (14.7) | |
3,4: Fibrous septa | 15 (12.9) | 15 (14.7) | 0.449 |
5: Nodular formation and incomplete cirrhosis | 4 (3.4) | 5 (4.9) | |
6: Established cirrhosis | 34 (29.3) | 38 (37.3) | |
Histological grade, n (%) | |||
Grade 1 | 34 (15.4) | 21 (13.9) | |
Grade 2 | 104 (47.1) | 76 (50.3) | 0.878 |
Grade 3 | 76 (34.4) | 48 (31.8) | |
Grade 4 | 7 (3.2) | 6 (4.0) | |
TNM stage, n (%) | |||
Stage I | 99 (48.1) | 76 (51.7) | |
Stage II | 51 (24.8) | 36 (24.5) | 0.293 |
Stage III | 51 (24.8) | 35 (23.8) | |
Stage IV | 5 (2.4) | 0 (0.0) | |